Neurogene (NGNE) Other Non-Current Liabilities (2013 - 2025)
Neurogene (NGNE) reported Other Non-Current Liabilities of $428000.0 for Q4 2025, down 40.39% on a YoY basis from $718000.0 in Q4 2024, and up 739.22% quarter-over-quarter from $51000.0 in Q3 2025.
Neurogene (NGNE) Other Non-Current Liabilities (2013 - 2025) Analysis & Trends
Neurogene has reported Other Non-Current Liabilities for 10 years, with the latest figure at $428000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities fell 40.39% year-over-year to $428000.0; the trailing twelve-month figure through Dec 2025 stood at $428000.0 (down 40.39% YoY), and the FY2025 full-year result was $428000.0, down 40.39% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $428000.0, up from $51000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.0 million in Q4 2023, with the low at $51000.0 in Q1 2025.
- Historically, Other Non-Current Liabilities has averaged $502777.8 across 3 years, with a median of $646000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities retreated 28.63% — and 2025, when it tumbled 94.05%.
- Neurogene's Other Non-Current Liabilities stood at $1.0 million in 2023, then dropped by 28.63% to $718000.0 in 2024, then plunged by 40.39% to $428000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $428000.0 (Q4 2025), $51000.0 (Q3 2025), and $51000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 428,000.00 |
| Sep 30, 2025 | 51,000.00 |
| Jun 30, 2025 | 51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 718,000.00 |
| Sep 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 717,000.00 |
| Mar 31, 2024 | 857,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Jun 30, 2019 | 2,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Dec 31, 2018 | 319,000.00 |
| Sep 30, 2018 | 343,000.00 |
| Jun 30, 2018 | 401,000.00 |
| Mar 31, 2018 | 443,000.00 |
| Dec 31, 2017 | 486,000.00 |
| Sep 30, 2017 | 513,000.00 |
| Jun 30, 2017 | 548,000.00 |
| Mar 31, 2017 | 562,000.00 |
| Dec 31, 2016 | 197,000.00 |